市場調査レポート

商品コード

1461506

ヒトインスリンの世界市場規模、シェア、成長分析、タイプ別、用途別、流通チャネル別-産業予測、2024～2031年

Global Human Insulin Market Size, Share, Growth Analysis, By Type, By Application, By Distribution channel - Industry Forecast 2024-2031

出版日: 2024年04月03日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 762,034円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 891,436円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,020,838円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.78円

全表示
概要
目次

概要

サンプル依頼リストに入れる

ヒトインスリンの世界市場規模は2022年に190億5,000万米ドルと評価され、予測期間（2024～2031年）のCAGRは1.7%で、2023年の193億7,000万米ドルから2031年までに221億7,000万米ドルに成長する展望です。

ヒトインスリンの世界市場は、糖尿病有病率の上昇に後押しされ、糖尿病を管理する上で世界的に重要な役割を果たしています。このセグメントは、ヒトインスリン製品を生産し、医療施設、薬局、世界中の患者に配布することにより、インスリンの需要の高まりに対応するよう努めています。国際糖尿病連合によると2045年までに7億人に達すると予測されている糖尿病診断の急激な増加が、市場の拡大を後押ししています。組換えDNA技術のような技術の進歩は、より安全で効果的なインスリン製剤を生み出し、その採用と市場成長を促進しています。アクセシビリティを向上させる努力にもかかわらず、インスリンの高コストは、特に低所得地域において、製造コストの上昇や規制の複雑さが妨げとなり、大きな障壁として根強く残っています。優れた効能を持つ従来のインスリンからアナログインスリンへの移行は一般的な動向となっており、市場成長をさらに後押ししています。さらに、利便性と正確性を提供するインスリン送達デバイスに対する需要が高まっており、コネクテッドデバイスや人工知能のような新技術がその採用を促進しています。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

ヒトインスリンの世界市場：タイプ別

市場概要
従来のヒトインスリンとアナログインスリン

ヒトインスリンの世界市場：用途別

市場概要
1型糖尿病
2型糖尿病
妊娠糖尿病

ヒトインスリンの世界市場：流通チャネル別

市場概要
病院薬局
小売薬局
オンライン薬局
糖尿病クリニック

ヒトインスリンの世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

Novo Nordisk（デンマーク）
Eli Lilly and Company（米国）
Sanofi（フランス）
Merck & Co., Inc.（米国）
Pfizer Inc.（米国）
AstraZeneca（英国）
Johnson & Johnson（米国）
Biocon Ltd.（インド）
Ypsomed AG（スイス）
Wockhardt Ltd.（インド）
Julphar（アラブ首長国連邦）
Gan & Lee Pharmaceuticals（中国）
Bioton S.A.（ポーランド）
Adocia（フランス）
Torrent Pharmaceuticals Ltd.（インド）
Berlin-Chemie AG（ドイツ）
SemBioSys Genetics Inc.（カナダ）
Biodel Inc.（米国）
Dongbao Enterprise Group Co., Ltd.（中国）
Tonghua Dongbao Pharmaceutical Co., Ltd.（中国）

Product Code: SQMIG35I2266

Global Human Insulin Market size was valued at USD 19.05 Billion in 2022 and is poised to grow from USD 19.37 Billion in 2023 to USD 22.17 Billion by 2031, at a CAGR of 1.7% during the forecast period (2024-2031).

The Global Human Insulin Market serves as a vital component in managing diabetes worldwide, propelled by the escalating prevalence of the condition. This sector endeavors to meet the mounting demand for insulin by producing and distributing human insulin products to healthcare facilities, pharmacies, and patients globally. The exponential increase in diabetes diagnoses, projected to reach 700 million by 2045 according to the International Diabetes Federation, fuels the market's expansion. Technological advancements like recombinant DNA technology have yielded safer and more effective insulin products, fostering their adoption and market growth. Despite efforts to enhance accessibility, the high cost of insulin persists as a significant barrier, especially in low-income regions, hindered by elevated production costs and regulatory complexities. Transitioning from traditional to analog insulin, with its superior efficacy, has become a prevalent trend, further propelling market growth. Additionally, there's a rising demand for insulin delivery devices, offering convenience and accuracy, with emerging technologies like connected devices and artificial intelligence driving their adoption.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Insulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Insulin Market Segmental Analysis

Global Human Insulin Market is segmented on the basis of type, application, distribution channel, and region. By type, the market is segmented into traditional human insulin and analog insulin. By application, the market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and diabetes clinics. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Human Insulin Market

The increasing incidence of diabetes globally serves as a major catalyst for the expansion of the worldwide human insulin market. According to the International Diabetes Federation, approximately 463 million adults had diabetes in 2019, a figure anticipated to climb to 700 million by 2045. This burgeoning population of individuals with diabetes creates a greater need for insulin, propelling market growth. For instance, nations such as China and India have experienced a surge in diabetes cases attributable to shifting lifestyles and dietary patterns, consequently driving up the demand for human insulin.

Restraints in the Global Human Insulin Market

Regulatory barriers and patent exclusivity pose significant obstacles in the human insulin market, constraining competition and market entry. Securing regulatory approvals for novel insulin products or biosimilars demands extensive testing and adherence to strict regulations. Furthermore, the exclusivity granted to specific insulin formulations restricts the proliferation of generic alternatives, thereby limiting patient choices and hindering market expansion. Notably, the dominance of certain long-acting insulin analogs under patent protection further impedes the introduction of biosimilar counterparts into the market.

Market Trends of the Global Human Insulin Market

A discernible shift is observed in the market as it moves away from conventional human insulin towards analog insulin, which provides benefits like quicker onset, shorter action duration, and enhanced glycemic control. Healthcare professionals and individuals with diabetes are progressively embracing analog insulin to attain superior management of the condition. Notably, long-acting analog insulin such as insulin glargine (Lantus) and insulin detemir (Levemir) have witnessed substantial market growth owing to their improved pharmacokinetic profiles.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Human Insulin Market by Type

Market Overview
Traditional human insulin and analog insulin

Global Human Insulin Market by Application

Market Overview
Type 1 diabetes
type 2 diabetes
and gestational diabetes

Global Human Insulin Market by Distribution channel

Market Overview
Hospital pharmacies
retail pharmacies
online pharmacies
and diabetes clinics

Global Human Insulin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ypsomed AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wockhardt Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Julphar (United Arab Emirates)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gan & Lee Pharmaceuticals (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioton S.A. (Poland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adocia (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Berlin-Chemie AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SemBioSys Genetics Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biodel Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dongbao Enterprise Group Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments